Eli Lilly's Once-Weekly Insulin Onswik Wins NICE Recommendation for UK Type 2 Diabetes Patients

NICE Draft Guidance and NHS Access Path

The UK's National Institute for Health and Care Excellence (NICE) issued a positive draft recommendation for Eli Lilly's once-weekly injectable insulin Onswik, clearing a key hurdle toward National Health Service availability for adults with type 2 diabetes. A positive NICE recommendation typically allows NHS coverage once pricing and supply terms are finalized. NICE's final draft guidance specifically highlighted benefits for patients who need assistance with injections because of sight loss, frailty, limited hand movement, or difficulty following the required steps, and said a weekly schedule could reduce dependence on caregivers and healthcare workers.

Reduction in Injection Burden and Eligible Population

According to NICE, hundreds of thousands of type 2 diabetes patients in England and Wales could eventually switch to a weekly injection, reducing their annual injections by 85%. Younger patients with type 2 diabetes may also benefit if the weekly schedule helps them balance treatment with work and daily routines. Diabetes UK's head of clinical, Douglas Twenefour, said the recommendation "is an important step towards giving people with type 2 diabetes greater flexibility in how their condition is managed."

Clinical Evidence From the QWINT Program

NICE's evaluation drew on late-stage data from Lilly's QWINT-1, QWINT-3, and QWINT-4 clinical trials, which showed non-inferior A1C reduction versus daily insulin across multiple patient groups. Onswik controlled blood glucose as effectively as two widely used daily basal insulins, insulin degludec and insulin glargine, while maintaining a similar safety profile. "This recommendation is the result of rigorous, evidence-based decision making, striking a balance between the benefits to patients and the best use of limited NHS funding," said Helen Knight, NICE's director of medicines evaluation.

Regulatory and Commercial Status

A Lilly spokesperson confirmed the company is "awaiting a decision from the MHRA on marketing authorization," a step required before Onswik can be formally approved and launched in Britain. The endorsement lands against a strained backdrop: by the end of 2025, corporations had pulled about £2 billion (roughly $2.7 billion) in planned UK investments amid disputes over drug pricing, and Merck and AstraZeneca previously paused UK expansion plans while Bristol Myers Squibb threatened to withhold a drug from the NHS over pricing disagreements.

Next Milestone

The next verifiable step is the UK Medicines and Healthcare products Regulatory Agency (MHRA) decision on marketing authorization for Onswik, which would allow Lilly to formally launch the therapy in Britain following NICE's final guidance.